Insider transactions

EDGAR

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
183 transactions, 6,532,788 shares
Sum of shares × price per share: 121,606,486.64

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 475

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-13 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,46612.14
139,197.24

Derived: shares × price per share. Exact value 139197.24.

389,268Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)11,46628.93
331,711.38

Derived: shares × price per share. Exact value 331711.38.

377,802Direct (D) Yes
F1, F5
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 to $29.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-13 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,466) — exercise price 12.14
Disposed (D)11,4660—0Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The option is fully vested and exercisable.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)11,88129.40
349,301.4

Derived: shares × price per share. Exact value 349301.40.

377,802Direct (D) Yes
F1, F4
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.74 to $29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—11,466Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The option is fully vested and exercisable.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13BOBULSKY SUSAN Officer: Chief Commercial Officer, MRD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,87532.00
60,000

Derived: shares × price per share. Exact value 60000.00.

387,475Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open filing 0001820885-26-000027 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,98330.29
150,935.07

Derived: shares × price per share. Exact value 150935.07.

384,700Direct (D) Yes
F1, F2
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,89831.22
215,355.56

Derived: shares × price per share. Exact value 215355.56.

377,802Direct (D) Yes
F1, F3
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.63, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-11 Filed 2026-11-13RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—23,347Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The option is fully vested and exercisable.
Open filing 0001780664-26-000055 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,98129.35
292,942.35

Derived: shares × price per share. Exact value 292942.35.

379,702Direct (D) Yes
F1, F5
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,90030.41
57,779

Derived: shares × price per share. Exact value 57779.00.

377,802Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—35,228Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The option is fully vested and exercisable.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12ROBINS CHAD M Director · Officer: CEO and Chairman
G

Bona fide gift

Common Stock
Disposed (D)100,0000.00
0

Derived: shares × price per share. Exact value 0.00.

2,080,518Direct (D) No
F1
  • F1 All shares to be sold to the Robins Nest Family Foundation.
Open filing 0001780649-26-000016 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,10028.87
31,757

Derived: shares × price per share. Exact value 31757.00.

388,583Direct (D) Yes
F1, F2
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.41 to $29.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,38130.15
252,687.15

Derived: shares × price per share. Exact value 252687.15.

380,202Direct (D) Yes
F1, F3
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,40030.58
73,392

Derived: shares × price per share. Exact value 73392.00.

377,802Direct (D) Yes
F1, F4
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $30.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-10RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—47,109Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The option is fully vested and exercisable.
Open filing 0001780664-26-000053 Read from the filing’s XML Dispute this row
2026-11-06 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-06 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8,40027.32
229,488

Derived: shares × price per share. Exact value 229488.00.

381,283Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-06 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,48127.88
97,050.28

Derived: shares × price per share. Exact value 97050.28.

377,802Direct (D) Yes
F1, F8
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F8 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-06 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—58,990Direct (D) Yes
F1, F9
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F9 The option is fully vested and exercisable.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,92626.10
154,668.6

Derived: shares × price per share. Exact value 154668.60.

383,757Direct (D) Yes
F1, F4
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,45526.88
146,630.4

Derived: shares × price per share. Exact value 146630.40.

378,302Direct (D) Yes
F1, F5
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50027.70
13,850

Derived: shares × price per share. Exact value 13850.00.

377,802Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—70,871Direct (D) Yes
F1, F9
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F9 The option is fully vested and exercisable.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,00025.78
103,120

Derived: shares × price per share. Exact value 103120.00.

385,683Direct (D) Yes
F1, F2
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,88126.60
209,634.6

Derived: shares × price per share. Exact value 209634.60.

377,802Direct (D) Yes
F1, F3
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-06RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—82,752Direct (D) Yes
F1, F9
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F9 The option is fully vested and exercisable.
Open filing 0001780664-26-000051 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)11,88125.98
308,668.38

Derived: shares × price per share. Exact value 308668.38.

377,802Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.65 to $26.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-11-03 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—94,633Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The option is fully vested and exercisable.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,29625.23
234,538.08

Derived: shares × price per share. Exact value 234538.08.

380,387Direct (D) Yes
F1, F4
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.88 to $25.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,58526.34
68,088.9

Derived: shares × price per share. Exact value 68088.90.

377,802Direct (D) Yes
F1, F5
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—106,514Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The option is fully vested and exercisable.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,48626.55
251,853.3

Derived: shares × price per share. Exact value 251853.30.

380,197Direct (D) Yes
F1, F2
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $27.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,39527.45
65,742.75

Derived: shares × price per share. Exact value 65742.75.

377,802Direct (D) Yes
F1, F3
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.21 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-03RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—118,395Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The option is fully vested and exercisable.
Open filing 0001780664-26-000049 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-10-29RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000047 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-10-29RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)11,88128.27
335,875.87

Derived: shares × price per share. Exact value 335875.87.

377,802Direct (D) Yes
F1, F6
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F6 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000047 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-10-29RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,881) — exercise price 12.14
Disposed (D)11,8810—130,276Direct (D) Yes
F1, F7
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F7 The option is fully vested and exercisable.
Open filing 0001780664-26-000047 Read from the filing’s XML Dispute this row
2026-10-28 Filed 2026-10-29RUBINSTEIN JULIE Officer: President and COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,88112.14
144,235.34

Derived: shares × price per share. Exact value 144235.34.

389,683Direct (D) Yes
F1
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
Open filing 0001780664-26-000047 Read from the filing’s XML Dispute this row
2026-10-28 Filed 2026-10-29RUBINSTEIN JULIE Officer: President and COO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)11,68128.44
332,207.64

Derived: shares × price per share. Exact value 332207.64.

378,002Direct (D) Yes
F1, F4
  • F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  • F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open filing 0001780664-26-000047 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
BENZENO SHARON Officer: Chief Commercial Ofc Imm MedStock Option (right to buy) Derivative security · underlying Common Stock113,457D As of 2026-06-29 Open filing 4
BENZENO SHARON Officer: Chief Commercial Ofc Imm MedCommon Stock 221,278D As of 2026-06-29 Open filing 4
BOBULSKY SUSAN Officer: Chief Commercial Officer, MRDStock Option (right to buy) Derivative security · underlying Common Stock180,029D As of 2025-03-04 Open filing 4
BOBULSKY SUSAN Officer: Chief Commercial Officer, MRDCommon Stock 387,475D As of 2026-11-11 Open filing 4
GRIFFIN MICHELLE RENEE DirectorStock Option (right to buy) Derivative security · underlying Common Stock0D As of 2026-06-25 Open filing 4
GRIFFIN MICHELLE RENEE DirectorCommon Stock 15,625D As of 2026-06-25 Open filing 4
HERSHBERG ROBERT DirectorStock Option (right to buy) Derivative security · underlying Common Stock0D As of 2026-08-18 Open filing 4
HERSHBERG ROBERT DirectorCommon Stock 46,683D As of 2026-08-18 Open filing 4
LO FRANCIS Officer: Chief People OfficerStock Option (right to buy) Derivative security · underlying Common Stock93,765D As of 2026-10-01 Open filing 4
LO FRANCIS Officer: Chief People OfficerCommon Stock 2,500I By You Jin Lee (spouse)As of 2026-10-05 Open filing 4
LO FRANCIS Officer: Chief People OfficerCommon Stock 220,867D As of 2026-10-01 Open filing 4
NEUPERT PETER M DirectorStock Option (right to buy) Derivative security · underlying Common Stock0D As of 2026-08-17 Open filing 4
NEUPERT PETER M DirectorCommon Stock 130,625D As of 2026-08-17 Open filing 4
OWEN KATEY EINTERZ DirectorStock Option (right to buy) Derivative security · underlying Common Stock23,726D As of 2025-03-04 Open filing 4
OWEN KATEY EINTERZ DirectorCommon Stock 66,100D As of 2026-08-31 Open filing 4
PISKEL KYLE Officer: Chief Financial OfficerStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2025-03-14 Open filing 4
PISKEL KYLE Officer: Chief Financial OfficerStock Option (right to buy) Derivative security · underlying Common Stock2,146D As of 2026-02-04 Open filing 4
PISKEL KYLE Officer: Chief Financial OfficerCommon Stock 256,725D As of 2026-05-18 Open filing 4
Pellini Michael J DirectorStock Option (right to buy) Derivative security · underlying Common Stock23,726D As of 2025-03-04 Open filing 4
Pellini Michael J DirectorCommon Stock 69,690D As of 2025-03-04 Open filing 4
ROBINS CHAD M Director · Officer: CEO and ChairmanStock Option (right to buy) Derivative security · underlying Common Stock0D As of 2026-08-18 Open filing 4
ROBINS CHAD M Director · Officer: CEO and ChairmanCommon Stock 2,080,518D As of 2026-11-09 Open filing 4
ROBINS HARLAN S Officer: Chief Scientific OfficerStock Option (Right to Buy) Derivative security · underlying Common Stock0D As of 2025-05-01 Open filing 4
ROBINS HARLAN S Officer: Chief Scientific OfficerStock Option (right to buy) Derivative security · underlying Common Stock0D As of 2026-07-21 Open filing 4
ROBINS HARLAN S Officer: Chief Scientific OfficerCommon Stock 812,058D As of 2026-07-21 Open filing 4
RUBINSTEIN JULIE Officer: President and COOStock Option (right to buy) Derivative security · underlying Common Stock0D As of 2026-11-13 Open filing 4
RUBINSTEIN JULIE Officer: President and COOCommon Stock 377,802D As of 2026-11-13 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 344

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
VIKING GLOBAL INVESTORS LP 29,993,708 SH866,818,161 dollarsUnchanged Prior quarter: 29,993,708Open filing 0001103804-26-000010 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager15,302,445 SH442,240,661 dollarsHigher by 163,286 Prior quarter: 15,139,159Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 6,436,045 SH186,001,701 dollarsHigher by 32,458 Prior quarter: 6,403,587Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager6,373,294 SH184,188,197 dollarsHigher by 1,747,435 Prior quarter: 4,625,859Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager5,702,859 SH164,813 dollarsHigher by 3,037,551 Prior quarter: 2,665,308Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 5,239,185 SH151,412,447 dollarsLower by 237,046 Prior quarter: 5,476,231Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager4,747,974 SH137,216,449 dollarsLower by 1,163,392 Prior quarter: 5,911,366Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
Driehaus Capital Management LLC 4,705,948 SH136,001,897 dollarsHigher by 2,178,245 Prior quarter: 2,527,703Open filing 0000938206-26-000066 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager3,720,520 SH107,541,913 dollarsHigher by 78,683 Prior quarter: 3,641,837Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
T. Rowe Price Investment Management, Inc. 3,586,441 SH103,649 dollarsHigher by 1,806,790 Prior quarter: 1,779,651Open filing 0001897612-26-000766 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager3,557,289 SH102,805,652 dollarsHigher by 98,901 Prior quarter: 3,458,388Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
LORD, ABBETT CO. LLC 3,319,996 SH95,948 dollarsHigher by 845,182 Prior quarter: 2,474,814Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row
Invesco Ltd. Partly reported under another manager3,227,360 SH93,270,705 dollarsHigher by 133,349 Prior quarter: 3,094,011Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager3,085,661 SH89,175,603 dollarsHigher by 101,434 Prior quarter: 2,984,227Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
UBS Group AG Option: Call Partly reported under another manager2,862,120 SH82,715,268 dollarsUnchanged Prior quarter: 2,862,120Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
PRINCIPAL FINANCIAL GROUP INC Partly reported under another manager2,445,689 SH70,680,414 dollarsHigher by 2,406,860 Prior quarter: 38,829Open filing 0001126328-26-000225 Filed 2026-11-02 Dispute this row
Nuveen, LLC Partly reported under another manager2,333,118 SH67,427,111 dollarsLower by 33,037 Prior quarter: 2,366,155Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager2,312,564 SH66,833,100 dollarsLower by 212,056 Prior quarter: 2,524,620Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
FRED ALGER MANAGEMENT, LLC 2,076,587 SH60,013,364 dollarsLower by 15,697 Prior quarter: 2,092,284Open filing 0001193125-26-463608 Filed 2026-11-16 Dispute this row
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Partly reported under another manager2,027,715 SH58,600,964 dollarsLower by 154,611 Prior quarter: 2,182,326Open filing 0001520354-26-000046 Filed 2026-11-13 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager1,990,000 SH57,511,000 dollarsHigher by 18,700 Prior quarter: 1,971,300Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
ARK Investment Management LLC 1,920,772 SH55,510,311 dollarsLower by 169,534 Prior quarter: 2,090,306Open filing 0001104659-26-126785 Filed 2026-11-13 Dispute this row
Aristotle Atlantic Partners, LLC Partly reported under another manager1,854,200 SH53,586,380 dollarsHigher by 15,687 Prior quarter: 1,838,513Open filing 0001398344-26-020100 Filed 2026-11-16 Dispute this row
WESTFIELD CAPITAL MANAGEMENT CO LP 1,826,631 SH52,789,636 dollarsLower by 2,441,014 Prior quarter: 4,267,645Open filing 0001177719-26-000022 Filed 2026-11-12 Dispute this row
TORONTO DOMINION BANK Option: Call 1,800,000 SH52,020,000 dollarsUnchanged Prior quarter: 1,800,000Open filing 0002052595-26-000123 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager1,529,232 SH44,194,804 dollarsHigher by 21,881 Prior quarter: 1,507,351Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager1,425,621 SH41,200,448 dollarsHigher by 1,157,182 Prior quarter: 268,439Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
OBERWEIS ASSET MANAGEMENT INC/ 1,256,802 SH36,321,578 dollarsLower by 1,949 Prior quarter: 1,258,751Open filing 0001213900-26-120411 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,244,315 SH35,960,704 dollarsHigher by 65,763 Prior quarter: 1,178,552Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 1,216,007 SH35,142,602 dollarsHigher by 711,098 Prior quarter: 504,909Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager1,213,213 SH35,061,856 dollarsLower by 675,975 Prior quarter: 1,889,188Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager1,143,790 SH33,055,532 dollarsLower by 586,254 Prior quarter: 1,730,044Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager1,132,945 SH32,742,214 dollarsHigher by 45,191 Prior quarter: 1,087,754Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
Sumitomo Mitsui Trust Group, Inc. Partly reported under another manager1,087,421 SH31,426,467 dollarsLower by 242,435 Prior quarter: 1,329,856Open filing 0001214659-26-013361 Filed 2026-10-29 Dispute this row
Amova Asset Management Americas, Inc. Partly reported under another manager1,087,421 SH31,426,467 dollarsLower by 242,435 Prior quarter: 1,329,856Open filing 0001140361-26-043552 Filed 2026-11-13 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager1,051,421 SH30,386,067 dollarsHigher by 550,966 Prior quarter: 500,455Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager1,050,381 SH30,356,060 dollarsHigher by 284,151 Prior quarter: 766,230Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager1,031,221 SH29,802,297 dollarsHigher by 601,992 Prior quarter: 429,229Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
PANAGORA ASSET MANAGEMENT INC 1,019,061 SH29,450,863 dollarsHigher by 241,446 Prior quarter: 777,615Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row
Blue Water Life Science Advisors, LP 1,010,145 SH29,193,191 dollarsUnchanged Prior quarter: 1,010,145Open filing 0001420506-26-002712 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 949,132 SH27,429,915 dollarsHigher by 14,423 Prior quarter: 934,709Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 946,628 SH27,357,549 dollarsHigher by 160,725 Prior quarter: 785,903Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager867,100 SH25,059,190 dollarsHigher by 564,300 Prior quarter: 302,800Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
FMR LLC Partly reported under another manager833,221 SH24,080,073 dollarsHigher by 123,687 Prior quarter: 709,534Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
FIRST TRUST ADVISORS LP 797,309 SH23,042,230 dollarsHigher by 379,486 Prior quarter: 417,823Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
Aberdeen Group plc Partly reported under another manager782,621 SH22,617,747 dollarsLower by 136,377 Prior quarter: 918,998Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row
MACKENZIE FINANCIAL CORP 740,004 SH21,386,116 dollarsNot in the prior quarter’s filings read Open filing 0001062993-26-005652 Filed 2026-11-02 Dispute this row
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 707,592 SH20,449,409 dollarsLower by 364,343 Prior quarter: 1,071,935Open filing 0000912938-26-001073 Filed 2026-11-12 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager705,008 SH18,830,764 dollarsHigher by 530,097 Prior quarter: 174,911Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
Qube Research Technologies Ltd 695,646 SH20,104,169 dollarsHigher by 215,914 Prior quarter: 479,732Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Ghisallo Capital Management LLC 5,000,000 PRN
  • Sixth Street Partners Management Company, L.P. 1,178,552 SH
  • Polar Asset Management Partners Inc. 272,571 SH
  • FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. 202,097 SH
  • SUSQUEHANNA ADVISORS GROUP, INC. 184,200 SH
  • ARISTEIA CAPITAL, L.L.C. 183,500 SH
  • EP Wealth Advisors, LLC 124,451 SH
  • SG Americas Securities, LLC 117,909 SH
  • CAPITAL FUND MANAGEMENT S.A. 85,062 SH
  • Assenagon Asset Management S.A. 47,766 SH
  • Jupiter Topco LLC 46,900 SH
  • COOKSON PEIRCE CO INC 40,449 SH
  • DIMENSIONAL FUND ADVISORS LP 31,324 SH
  • INTECH INVESTMENT MANAGEMENT LLC 30,284 SH
  • Jackson Creek Investment Advisors LLC 29,091 SH
  • Penserra Capital Management LLC 23,102 SH
  • Jain Global LLC 19,846 SH
  • Ares Systematic Credit Ltd 19,359 SH
  • Arrowpoint Investment Partners (Singapore) Pte. Ltd. 15,149 SH
  • MIRABELLA FINANCIAL SERVICES LLP 10,999 SH
  • Amundi 10,419 SH
  • Avior Wealth Management, LLC 10,408 SH
  • SEVEN GRAND MANAGERS, LLC 10,370 SH
  • BOLTON SECURITIES CORPORATION 10,000 SH
  • Headlands Technologies LLC 9,718 SH
  • Integrated Wealth Concepts LLC 2,159 SH
  • Bayforest Capital Ltd 1,504 SH
  • MATHER GROUP, LLC. 1,095 SH
  • MCF Advisors LLC 833 SH
  • Optiver Holding B.V. 762 SH
  • SMA Capital LLC 485 SH
  • SALEM INVESTMENT COUNSELORS INC 215 SH
  • Cordant, Inc. 100 SH
  • CVA Family Office, LLC 40 SH
  • Stone House Investment Management, LLC 39 SH
  • BERTHEL, FISHER COMPANY FINANCIAL SERVICES, INC. 35 SH
  • Covestor Ltd 32 SH
  • NATIONAL BANK OF CANADA /FI/ 23 SH
  • Kingdom Financial Group LLC. 23 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

13F filers report holding between 42.56% and 103.00% of shares outstanding.

Quarter ending 2026-09-30, against 161,876,694 shares on the cover dated 2026-10-30.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 33268,896,989166,731,9428,935
2026-06-30 30565,732,257156,635,7459,178
2026-03-31 30066,739,062151,612,2709,173
2025-12-31 28261,116,464149,998,2919,222
2025-09-30 26963,261,065145,333,4038,469
2025-06-30 24270,606,881148,454,0598,516
2025-03-31 22577,755,814154,736,8958,518
2024-12-31 20976,102,480143,114,8378,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
VIKING GLOBAL INVESTORS LP Common Stock, par value $0.0001 per share18.829,993,70803/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
VIKING GLOBAL PERFORMANCE LLC Common Stock, par value $0.0001 per share13.822,002,18903/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
Viking Global Equities II LP Common Stock, par value $0.0001 per share0.3440,04603/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
Viking Global Equities Master Ltd. Common Stock, par value $0.0001 per share13.521,562,14303/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
Viking Long Fund GP LLC Common Stock, par value $0.0001 per share57,991,51903/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
Viking Long Fund Master Ltd. Common Stock, par value $0.0001 per share57,991,51903/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
HALVORSEN OLE ANDREAS Common Stock, par value $0.0001 per share18.829,993,70803/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
Shabet Rose Sharon Common Stock, par value $0.0001 per share18.829,993,70803/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0000905148-26-002432 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 6Open filing 0000102909-26-000534 Dispute this row
BlackRock, Inc. Common Stock7.911,992,44812/31/2025 Filed 2026-01-21SCHEDULE 13G/AAmendment 3Open filing 0002012383-26-000632 Dispute this row
Rubric Capital Management LP Common stock, par value $0.0001 per share4.126,256,847.0006/30/2025 Filed 2025-07-09SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-066700 Dispute this row
David Rosen Common stock, par value $0.0001 per share4.126,256,847.0006/30/2025 Filed 2025-07-09SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-066700 Dispute this row
Rubric Capital Management LP Common Stock, $0.0001 par value9.7614,400,000— Filed 2024-11-13SC 13GRead from the cover page textOpen filing 0001104659-24-117737 Dispute this row
David Rosen Common Stock, $0.0001 par value9.7614,400,000— Filed 2024-11-13SC 13GRead from the cover page textOpen filing 0001104659-24-117737 Dispute this row
The Vanguard Group Adaptive Biotechnologies Corp7.2110,639,440— Filed 2024-11-12SC 13G/AAmendment 5Read from the cover page textOpen filing 0000932471-24-000885 Dispute this row
Nikko Asset Management Americas, Inc. Common stock, par value $0.0001 per share5.247,733,884— Filed 2024-11-08SC 13GRead from the cover page textOpen filing 0001140361-24-045810 Dispute this row
Sumitomo Mitsui Trust Group, Inc. (“SMTG”) Common stock, par value $0.0001 per share5.247,733,884— Filed 2024-11-05SC 13GRead from the cover page textOpen filing 0001214659-24-018424 Dispute this row
Nikko Asset Management Co., Ltd. (“NAM”) Common stock, par value $0.0001 per share5.247,733,884— Filed 2024-11-05SC 13GRead from the cover page textOpen filing 0001214659-24-018424 Dispute this row
The Vanguard Group Adaptive Biotechnologies Corp7.2110,639,440— Filed 2024-11-04SC 13GAmendment 4Read from the cover page textOpen filing 0000932471-24-000260 Dispute this row
Integrated Core Strategies (US) LLC COMMON STOCK, PAR VALUE $0.0001 PER SHARE6.39,303,890— Filed 2024-10-11SC 13G/AAmendment 1Read from the cover page textOpen filing 0001319244-24-000051 Dispute this row
Millennium Management LLC COMMON STOCK, PAR VALUE $0.0001 PER SHARE6.49,400,573— Filed 2024-10-11SC 13G/AAmendment 1Read from the cover page textOpen filing 0001319244-24-000051 Dispute this row
Millennium Group Management LLC COMMON STOCK, PAR VALUE $0.0001 PER SHARE6.49,400,573— Filed 2024-10-11SC 13G/AAmendment 1Read from the cover page textOpen filing 0001319244-24-000051 Dispute this row
Israel A. Englander COMMON STOCK, PAR VALUE $0.0001 PER SHARE6.49,400,573— Filed 2024-10-11SC 13G/AAmendment 1Read from the cover page textOpen filing 0001319244-24-000051 Dispute this row
Integrated Core Strategies (US) LLC COMMON STOCK, PAR VALUE $0.0001 PER SHARE5.27,731,846— Filed 2024-05-28SC 13GRead from the cover page textOpen filing 0001319244-24-000044 Dispute this row
Millennium Management LLC COMMON STOCK, PAR VALUE $0.0001 PER SHARE5.37,750,133— Filed 2024-05-28SC 13GRead from the cover page textOpen filing 0001319244-24-000044 Dispute this row
Millennium Group Management LLC COMMON STOCK, PAR VALUE $0.0001 PER SHARE5.37,750,133— Filed 2024-05-28SC 13GRead from the cover page textOpen filing 0001319244-24-000044 Dispute this row
Israel A. Englander COMMON STOCK, PAR VALUE $0.0001 PER SHARE5.37,750,133— Filed 2024-05-28SC 13GRead from the cover page textOpen filing 0001319244-24-000044 Dispute this row
Viking Global Investors LP Common stock20.729,993,708— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
Viking Global Performance LLC Common stock15.222,002,189— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
Viking Global Equities II LP Common stock0.3440,046— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
Viking Global Equities Master Ltd. Common stock14.921,562,143— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
Viking Long Fund GP LLC Common stock5.57,991,519— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
Viking Long Fund Master Ltd. Common stock5.57,991,519— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
O. Andreas Halvorsen Common stock20.729,993,708— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
David C. Ott Common stock20.729,993,708— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
Rose S. Shabet Common stock20.729,993,708— Filed 2024-02-14SC 13G/AAmendment 3Read from the cover page textOpen filing 0000905148-24-000623 Dispute this row
The Vanguard Group - 23-1945930 Name of issuer: Adaptive Biotechnologies Corp8.8212,767,684— Filed 2024-02-13SC 13G/AAmendment 3Read from the cover page textOpen filing 0001104659-24-020175 Dispute this row
ARK Investment Management LLC Common stock8.8512,806,513— Filed 2024-01-29SC 13G/AAmendment 1Read from the cover page textOpen filing 0001104659-24-007709 Dispute this row
BlackRock, Inc. Common Stock7.911,421,554— Filed 2024-01-26SC 13GRead from the cover page textOpen filing 0001086364-24-004337 Dispute this row
BlackRock, Inc. Common Stock8.712,374,197— Filed 2023-02-13SC 13GRead from the cover page textOpen filing 0001306550-23-008655 Dispute this row
ARK Investment Management LLC Common stock6.439,201,245— Filed 2023-02-10SC 13GRead from the cover page textOpen filing 0001104659-23-018086 Dispute this row
The Vanguard Group - 23-1945930 Name of issuer: Adaptive Biotechnologies Corp.8.2511,794,168— Filed 2023-02-09SC 13G/AAmendment 2Read from the cover page textOpen filing 0001104659-23-015200 Dispute this row
T. ROWE PRICE ASSOCIATES, INC. COMMON STOCK2.94,081,518— Filed 2022-09-12SC 13G/AAmendment 2Read from the cover page textOpen filing 0000080255-22-002541 Dispute this row
T. ROWE PRICE NEW HORIZONS FUND, INC. COMMON STOCK1.21,849,399— Filed 2022-09-12SC 13G/AAmendment 2Read from the cover page textOpen filing 0000080255-22-002541 Dispute this row
Viking Global Investors LP Common stock21.329,993,708— Filed 2022-02-14SC 13G/AAmendment 2Read from the cover page textOpen filing 0001140361-22-005381 Dispute this row
Viking Global Performance LLC Common stock15.622,002,189— Filed 2022-02-14SC 13G/AAmendment 2Read from the cover page textOpen filing 0001140361-22-005381 Dispute this row
Viking Global Equities II LP Common stock0.3440,046— Filed 2022-02-14SC 13G/AAmendment 2Read from the cover page textOpen filing 0001140361-22-005381 Dispute this row
Viking Global Equities Master Ltd. Common stock15.321,562,143— Filed 2022-02-14SC 13G/AAmendment 2Read from the cover page textOpen filing 0001140361-22-005381 Dispute this row
Viking Long Fund GP LLC Common stock5.77,991,519— Filed 2022-02-14SC 13G/AAmendment 2Read from the cover page textOpen filing 0001140361-22-005381 Dispute this row
Viking Long Fund Master Ltd. Common stock5.77,991,519— Filed 2022-02-14SC 13G/AAmendment 2Read from the cover page textOpen filing 0001140361-22-005381 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to ADAPTIVE BIOTECHNOLOGIES CORPORATION